Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,050 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cell Transfer Clear all

Conditions: Acquired Immunodeficiency Syndrome, HIV Infection
Interventions: White blood cell infusion; Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Melanoma, Unresectable Melanoma, Melanoma
Interventions: Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period; Biological
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 20 more

Conditions: Hematopoietic Cell Transplant
Interventions: Virtual exercise and rehabilitation program; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 8 Years to 23 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hepatocellular Carcinoma
Interventions: HepaSphere/QuadraSphere Microspheres, PVA, lipiodol, doxorubicin; Device · Procedure
Lead sponsor: Merit Medical Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 18
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 13 more

Conditions: Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer
Interventions: AutoSCT OR CAR T-cell Therapy, GDP, Epcoritamab; Procedure · Drug
Lead sponsor: Vijendra Singh; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Indianapolis, Indiana • Detroit, Michigan • Dallas, Texas + 1 more

Conditions: Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)
Interventions: Tirapazamine, Cisplatin, 5-fluorouracil, Radiotherapy (RT); Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 17 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2005
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Amivantamab, Olomorasib; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: New York, New York • Fairfax, Virginia

Conditions: Non-small Cell Lung Cancer
Interventions: CyberKnife Stereotactic Radiosurgery; Radiation
Lead sponsor: Accuray Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2021
U.S. locations: 21
States / cities: Phoenix, Arizona • Fresno, California • Palo Alto, California + 18 more

Conditions: Relapsed Refractory Multiple Myeloma
Interventions: NEXI-002 T Cells; Biological
Lead sponsor: NexImmune Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 6
States / cities: Duarte, California • Orlando, Florida • Boston, Massachusetts + 3 more

Conditions: Mycosis Fungoides, Sezary Syndrome
Interventions: A matched peripheral donor stem cells, cyclosporine, fludarabine, Campath; Other · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: COVID-19, Long Haul
Interventions: Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Multidisciplinary approach; Drug · Diagnostic Test · Biological + 3 more
Lead sponsor: Well- Konnect Healthcare Services and Research Firm; Network
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Squamous Cell Carcinoma
Interventions: Educational Intervention, Placebo; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Interventions: CD19.CAR-multiVST for Group A, CD19.CAR-multiVST for Group B; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2040
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Colorectal Cancer
Interventions: Gene Modified T Cells; Biological
Lead sponsor: Roger Williams Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Metastatic Melanoma
Interventions: Lifileucel; Biological
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 23
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 19 more

Conditions: Carcinoma, Squamous Cell of Head and Neck
Interventions: Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT); Drug · Radiation
Lead sponsor: Julie E. Bauman, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Severe Combined Immunodeficiency
Interventions: ADA PBSC, ADA Umbilical Cord Blood Cells, Transduced Lymphocytes; Drug
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1990 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease
Interventions: Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a; Biological
Lead sponsor: David Williams; Other
Eligibility: 13 Years to 40 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 9
States / cities: Los Angeles, California • Oakland, California • Sacramento, California + 4 more

Conditions: Non Small Cell Lung Cancer
Interventions: Pembrolizumab, stereotactic radiation therapy (SRT), Surgery (Non-interventional, standard of care); Drug · Radiation · Procedure
Lead sponsor: Sue Yom; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Parkinson's Disease
Interventions: MSK-DA01, MSK-DA01 Cell Delivery Device; Biological · Device
Lead sponsor: BlueRock Therapeutics; Industry
Eligibility: 50 Years to 78 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Orange, California • New York, New York

Conditions: Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Interventions: ER-100 epigenetic therapy; Genetic
Lead sponsor: Life Biosciences Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: Glendale, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Heme Malignancy
Interventions: Progressive Muscle Relaxation delivered via Virtual Reality; Combination Product
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Leukemia, Lymphoma, Non-Hodgkin, Hematologic Diseases, Acute GVHD
Interventions: Sirolimus, MMF, BCNU, VP-16, CY, FTBI, BU; Drug
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Lymphoma
Interventions: Radiation, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; Radiation · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

White Blood Cell Infusions to Treat HIV Infection

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Virtual Rehabilitation in HCT

HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer

Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients

CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA)

Trial of Second Generation Designer T Cells in Colorectal Carcinoma

Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study

A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)

Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer

Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease

Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

Progressive Muscle Relaxation Delivered Via Virtual Reality - an Intervention for Patients Undergoing Cellular Therapy

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

Stage I/II Nasal NK Cell Lymphoma